Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
630 Leser
Artikel bewerten:
(2)

Syqe Medical Announces Agreement with Israeli Ministry of Defence to Provide the SyqeAir Technology to Veterans

Finanznachrichten News

TEL AVIV, Israel, Feb. 15, 2023 /PRNewswire/ -- Syqe Medical, the developer of innovative technologies in the world of medical devices, is pleased to announce the signing of an agreement with the Israeli Ministry of Defence to supply the SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis by inhalation through the company's ground-breaking platform. This first-of-its-kind agreement allows veterans treated with medical cannabis using the SyqeAir Inhaler and Cartridges to obtain them directly in the same way they access pharmaceutical drugs, thus, positioning SyqeAir's precise, uniform, and consistent treatment as the standard of care in the field of medical cannabis.

SyqeAir Metered-Dose Inhaler and Cannabis Cartridges for precise, consistent, and safe medical cannabis treatment.

The SyqeAir Inhaler is a revolutionary device that allows patients to effectively and accurately manage their medical cannabis treatment, ensuring optimal therapeutic benefit. It is composed of a unique, patented, metered-dose system that precisely controls the amount of cannabis delivered to the patient with each inhalation. This allows for precise dosing and a high level of patient control over their treatment. The SyqeAir Inhaler is CE (European standard) and MDL (Health Canada) approved and clinically validated by 3 clinical trials and real-world evidence publications, demonstrating its safety and efficacy.

The inhaler is designed for easy home use as well as a hospital setting. The pre-loaded cartridge contains 60 uniform doses of pharmaceutical-grade, standardized raw cannabis flowers grown by the Dutch company Bedrocan. From the moment the cartridge is inserted into the inhaler, the inhaler is ready for immediate use without any prior preparations or the need to handle the cannabis directly so that patients can take their treatment discreetly and as part of their daily routine like any other medication.

Hagit Kamin, CEO of SyqeAir, said: "We are proud of the strategic partnership with the Ministry of Defence and the opportunity to bring our breakthrough technology, the SyqeAir Inhaler, to veterans in need of medical cannabis treatment. It is our privilege to help veterans who mainly suffer from chronic pain and PTSD to establish a functioning daily routine for themselves, and we are honored for the opportunity to make a positive impact on their lives.

Jacob Vogel, Director of Global Sales and Business Development, added: "It's been a long journey to get to this point, but it's truly rewarding to see the impact that the SyqeAir Inhaler has on the lives of our patients. The fact that we are able to provide veterans with a treatment option that has a real, positive impact on their daily functionality makes all the hard work worth it. We hope this partnership will serve as a model for other countries to follow in providing veterans with the best possible medical care."

About Syqe Medical

Syqe Medical is a pioneering MedTech company founded with the mission to relieve the suffering of as many patients as possible, in the fastest possible way, through advanced technologies. Syqe disrupted the pharmaceutical industry with their revolutionary technologies capable of delivering uniform doses of molecules by inhalation. The company's flagship product, the SyqeAir Inhaler, is the world's only platform that enables physicians and patients to control medical cannabis treatment with metered, precise, and consistent doses, ensuring optimal therapeutic benefit.

Contact

Phone. +972-3-376-7338
Email. info@syqemed.com
Website. www.syqe.com

Photo - https://mma.prnewswire.com/media/2002241/SyqeAir.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/syqe-medical-announces-agreement-with-israeli-ministry-of-defence-to-provide-the-syqeair-technology-to-veterans-301746526.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.